• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

rischind@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
Bachelors Degree (Honours)
Monash University
Doctorate (Research)
Monash University
ORCID

0000-0002-3368-0386

Prof Danny Rischin

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

523 Scholarly works
8 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
    DOI: 10.1016/j.jaad.2025.11.080
  • 2026

    Journal article

    INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    DOI: 10.1158/1078-0432.CCR-25-1197
  • 2026

    Journal article

    Prospective Evaluation of Patient Priorities in Human Papillomavirus-Driven Oropharyngeal Cancer Using the Chicago Priorities Scale: Considerations for Future Clinical Trial Design
    DOI: 10.1016/j.ijrobp.2025.08.053
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Expanding the Role of Immunotherapy in Cutaneous and Mucosal Head and Neck Squamous Cell Carcinomas
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Novel Treatment of Radiation Associated Dysphagia With Statins (TRADstat)
  • 2024

    Journal article

    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
    DOI: 10.1186/s12943-024-02048-1
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    Defining the Role of Immunotherapy and Immune Biomarkers in Head and Neck and Cutaneous Squamous Cell Carcinomas
Danny Rischin

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Examining CD103 Tissue-Resident Memory T Cells in Nasopharyngeal Carcinoma
    DOI: 10.1002/hed.70026
  • 2026

    Journal article

    Adjuvant nivolumab for resected high-risk head and neck cancer
    DOI: 10.1016/S0140-6736(26)00133-9
  • 2026

    Journal article

    Radiation Therapy Target Objectives for Tonsillar Cancer Treated With Unilateral Radiation Therapy—a Replanning Study From TROG 12.01
    DOI: 10.1016/j.ijrobp.2025.12.058
  • 2025

    Journal article

    Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01
    DOI: 10.1002/hed.28245
  • 2025

    Journal article

    Evaluating CD103 intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer
    DOI: 10.1016/j.oraloncology.2025.107792
  • 2025

    Journal article

    The authors reply
    DOI: 10.1056/NEJMc2513309
  • 2025

    Journal article

    EXPLORING TRANSCRIPTIONAL SUBTYPES AND IMMUNE MARKERS IN BEACON; PHASE II STUDY OF ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
    DOI: 10.1016/j.ijgc.2025.102500

RECENT PROJECTS

  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Expanding the Role of Immunotherapy in Cutaneous and Mucosal Head and Neck Squamous Cell Carcinomas

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224